nach oben

Cancer and Metastasis Reviews

Erschienen in:

03.01.2022 | Non-Thematic Review

Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance

verfasst von: Minal Garg

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Strong association of cancer incidence and its progression with mortality highlights the need to decipher the cellular and molecular mechanisms that drive tumor cells to rapidly progress to metastatic disease and therapy resistance. Epithelial-mesenchymal plasticity (EMP) emerged as a key regulator of metastatic outgrowth. It allows neoplastic epithelial cells to delaminate from their neighbors either individually or collectively, traverse the extracellular matrix (ECM) barrier, enter into the circulation, and establish distal metastases. Plasticity between epithelial and mesenchymal states and the existence of hybrid epithelial/mesenchymal (E/M) phenotypes are increasingly being reported in different tumor contexts. Small subset of cancer cells with stemness called cancer stem cells (CSCs) exhibit plasticity, possess high tumorigenic potential, and contribute to high degree of tumoral heterogeneity. EMP characterized by the presence of dynamic intermediate states is reported to be influenced by (epi)genomic reprograming, growth factor signaling, inflammation, and low oxygen generated by tumor stromal microenvironment. EMP alters the genotypic and phenotypic characteristics of tumor cells/CSCs, disrupts tissue homeostasis, induces the reprogramming of angiogenic and immune recognition functions, and renders tumor cells to survive hostile microenvironments and resist therapy. The present review summarizes the roles of EMP in tumor invasion and metastasis and provides an update on therapeutic strategies to target the metastatic and refractory cancers.

Marusyk, A., Almendro, V., & Polyak, K. (2012). Intra-tumour heterogeneity: A looking glass for cancer? Nature Reviews Cancer, 12, 323–334. https://doi.org/10.1038/nrc3261CrossRefPubMed

Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575, 299–309. https://doi.org/10.1038/s41586-019-1730-1CrossRefPubMedPubMedCentral

Hass, R., von der Ohe, J., & Ungefroren, H. (2020). The intimate relationship among EMT MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to be exploited for therapeutic purposes. Cancers, 12, 3674.CrossRefPubMedCentral

Garg, M. (2018). Epithelial plasticity and metastatic Cascade. Expert OpinTher Targets, 22(1), 5–7. https://doi.org/10.1080/14728222.2018.1407312CrossRef

Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discov, 9(7), 837–851.CrossRefPubMedPubMedCentral

Bhatia, S., Wang, P., Toh, A., & Thompson, E. W. (2020). New insights into the role of phenotypic plasticity and EMT in driving cancer progression. Frontiers Mol Bioscience, 7, 71. https://doi.org/10.3389/fmolb.2020.00071CrossRef

Yu, Y., Ramena, G., & Elble, R. C. (2012). The role of cancer stem cells in relapse of solid tumors. Frontiers in Bioscience, 4, 1528–1541. https://doi.org/10.2741/478CrossRef

Garg, M. (2017). Epithelial plasticity and cancer stem cells: Major mechanisms of cancer pathogenesis and therapy resistance. World J Stem Cells, 9(8), 118–126. https://doi.org/10.4252/wjsc.v9.i8.118CrossRefPubMedPubMedCentral

Bhatia, R., Holtz, M., Niu, N., Gray, R., Synder, D. S., Sawyers, C. L., et al. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, 4701–4707. https://doi.org/10.1182/blood-2002-09-2780CrossRefPubMed

10.

Poltavets, V., Kochetkova, M., Pitson, S. M., & Samuel, M. S. (2018). The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Frontiers in Oncology, 8, 431. https://doi.org/10.3389/fonc.2018.00431CrossRefPubMedPubMedCentral

11.

Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. (2016). EMT: 2016. Cell, 166, 21–45. https://doi.org/10.1016/j.cell.2016.06.028CrossRefPubMed

12.

Garg, M., & Singh, R. (2019). Epithelial-to-mesenchymal transition: Event and core associates in bladder cancer. Frontiers in Bioscience, 11, 150–165. PMID: 31136970.CrossRef

13.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119, 1420–1428. https://doi.org/10.1172/jci39104CrossRefPubMedPubMedCentral

14.

Greenburg, G., & Hay, E. D. (1982). Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. Journal of Cell Biology, 95, 333–339. https://doi.org/10.1083/jcb.95.1.333CrossRefPubMed

15.

Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9, 265–273. https://doi.org/10.1038/nrc2620CrossRefPubMed

16.

Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019). Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nature Reviews Cancer, 19, 716–732. https://doi.org/10.1038/s41568-019-0213-xCrossRefPubMedPubMedCentral

17.

Dongre, A., & Weinberg, R. A. (2019). New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology, 34, 466-482.e6. https://doi.org/10.1038/s41580-018-0080-4CrossRef

18.

Theveneau, E., Marchant, L., Kuriyama, S., Gull, M., Moepps, B., Parsons, M., et al. (2010). Collective chemotaxis requires contact-dependent cell polarity. Developmental Cell, 19, 39–53. https://doi.org/10.1016/j.devcel.2010.06.012CrossRefPubMedPubMedCentral

19.

Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Jinyang, Li., Yuan, S., et al. (2018). EMT subtype influences epithelial plasticity and mode of cell migration. Developmental Cell, 45(6), 681-695.e4.CrossRefPubMedPubMedCentral

20.

Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., et al. (2018). Identification of the tumour transition states occurring during EMT. Nature, 556, 463–468. https://doi.org/10.1038/s41586-018-0040-3CrossRefPubMed

21.

Godin, L., Balsat, C., Van Eycke, Y.-R., Allard, J., Royer, C., Remmelink, M., et al. (2020). A novel approach for quantifying cancer cells showing hybrid epithelial/mesenchymal states in large series of tissue samples: Towards a new prognostic marker. Cancers (Basel), 12(4), 906.CrossRefPubMedCentral

22.

Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., & Kirchner, T. (2005). Opinion: Migrating cancer stem cells—An integrated concept of malignant tumour progression. Nature Reviews Cancer, 5, 744–749. https://doi.org/10.1038/nrc1694CrossRefPubMed

23.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704–715. https://doi.org/10.1016/j.cell.2008.03.027CrossRefPubMedPubMedCentral

24.

Hojo, N., Huisken, A. L., Wang, H., Chirshev, E., Kim, N. S., Nguyen, S. M., et al. (2018). Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer. Science and Reports, 8, 8704. https://doi.org/10.1038/s41598-018-27021-zCrossRef

25.

Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., et al. (2006). Cancer stem cells – Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Research, 66, 9339–9344. https://doi.org/10.1158/0008-5472.CAN-06-3126CrossRefPubMed

26.

Morel, A. P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., & Puisieux, A. (2008). Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE, 3, e2888. https://doi.org/10.1371/journal.pone.0002888CrossRefPubMedPubMedCentral

27.

Tang, D. G. (2012). Understanding cancer stem cell heterogeneity and plasticity. Cell Research, 22, 457–472. https://doi.org/10.1038/cr.2012.13CrossRefPubMedPubMedCentral

28.

Pattabiraman, D. R., & Weinberg, R. A. (2014). Tackling the cancer stem cells - what challenges do they pose? Nature Reviews. Drug Discovery, 13, 497–512. https://doi.org/10.1038/nrd4253CrossRefPubMedPubMedCentral

29.

Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23, 1124–1134. https://doi.org/10.1038/nm.4409CrossRefPubMed

30.

Lytle, N. K., Barber, A. G., & Reya, T. (2018). Stem cell fate in cancer growth, progression and therapy resistance. Nature Reviews Cancer, 18, 669–680. https://doi.org/10.1038/s41568-018-0056-xCrossRefPubMedPubMedCentral

31.

Jolly, M. K., Mani, S. A., & Levine, H. (2018). Hybrid epithelial/mesenchymal phenotype(s): The ‘fittest’ for metastasis? BiochimBiophys Acta Rev Cancer, 1870, 151–157. https://doi.org/10.1016/j.bbcan.2018.07.001CrossRef

32.

Bierie, B., Pierce, S. E., Kroeger, C., Stover, D. G., Pattabiraman, D. R., Thiru, P., et al. (2017). Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proceedings of the National academy of Sciences of the United States of America, 114, E2337–E2346. https://doi.org/10.1073/pnas.1618298114CrossRefPubMedPubMedCentral

33.

Kröger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., et al. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proceedings of the National academy of Sciences of the United States of America, 116, 7353–7362. https://doi.org/10.1073/pnas.1812876116CrossRefPubMedPubMedCentral

34.

Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., et al. (2014). Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep, 2, 78–91. https://doi.org/10.1016/j.stemcr.2013.11.009CrossRef

35.

Colacino, J. A., Azizi, E., Brooks, M. D., Harouaka, R., Fouladdel, S., McDermott, S. P., et al. (2018). Heterogeneity of human breast stem and progenitor cells as revealed by transcriptional profiling. Stem Cell Rep, 10, 1596–1609. https://doi.org/10.1016/j.stemcr.2018.03.001CrossRef

36.

Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J. C., & Farace, F. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer, 105, 1338–1341. https://doi.org/10.1038/bjc.2011.405CrossRefPubMedPubMedCentral

37.

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339, 580–584. https://doi.org/10.1126/science.1228522CrossRefPubMedPubMedCentral

38.

Hyun, K. A., Koo, G. B., Han, H., Sohn, J., Choi, W., Kim, S. I., et al. (2016). Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget, 7, 24677–24687. https://doi.org/10.18632/oncotarget.8250CrossRefPubMedPubMedCentral

39.

Zhao, R., Cai, Z., Li, S., Cheng, Y., Gao, H., Liu, F., et al. (2017). Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget, 8, 9293–9302. https://doi.org/10.18632/oncotarget.14065CrossRefPubMed

40.

Bocci, F., Gearhart-Serna, L., Boareto, M., Ribeiro, M., Ben-Jacob, E., Devi, G. R., et al. (2019). Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proceedings of the National academy of Sciences of the United States of America, 116(1), 148–157. https://doi.org/10.1073/pnas.1815345116CrossRefPubMed

41.

Yoon, C., Cho, S.-J., Chang, K. K., Park, D. J., Ryeom, S. W., & Yoon, S. S. (2017). Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Molecular Cancer Research, 15(8), 1106–1116. https://doi.org/10.1158/1541-7786.MCR-17-0053CrossRefPubMed

42.

Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research, 65, 9328–9337. https://doi.org/10.1158/0008-5472.CAN-05-1343CrossRefPubMed

43.

Burman, D. R., Das, S., Das, C., & Bhattacharya, R. (2021). Alternative splicing modulates cancer aggressiveness: Role in EMT/metastasis and chemoresistance. Molecular Biology Reports, 48(1), 897–914.CrossRef

44.

Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T., et al. (2015). Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 527, 472–476. https://doi.org/10.1038/nature15748CrossRefPubMedPubMedCentral

45.

Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature, 527, 525–530. https://doi.org/10.1038/nature16064CrossRefPubMedPubMedCentral

46.

Marcucci, F., Stassi, G., & De Maria, R. (2016). Epithelial-mesenchymal transition: A new target in anticancer drug discovery. Nature Reviews. Drug Discovery, 15, 311–325. https://doi.org/10.1038/nrd.2015.13CrossRefPubMed

47.

Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell, 139, 891–906. https://doi.org/10.1016/j.cell.2009.10.027CrossRefPubMedPubMedCentral

48.

Boyle, S. T., Kular, J., Nobis, M., Ruszkiewicz, A., Timpson, P., & Samuel, M. S. (2018). Acute compressive stress activates RHO/ROCK-mediated cellular processes. Small GTPases, 17, 1–17. https://doi.org/10.1080/21541248.2017.1413496CrossRef

49.

Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., et al. (2013). Procollagen lysyl hydroxylase 2 is essential for hypoxia induced breast cancer metastasis. Molecular Cancer Research, 11, 456–466. https://doi.org/10.1158/1541-7786.MCR-12-0629CrossRefPubMed

50.

Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., et al. (2013). Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Research, 73, 3285–3296. https://doi.org/10.1158/0008-5472.CAN-12-3963CrossRefPubMedPubMedCentral

51.

Wolf, K., Wu, Y. I., Liu, Y., Geiger, J., Tam, E., Overall, C., et al. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature Cell Biology, 9, 893–904. https://doi.org/10.1038/ncb1616CrossRefPubMed

52.

Taylor, M. A., Amin, J. D., Kirschmann, D. A., & Schiemann, W. P. (2011). Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-beta signaling in breast cancer cells. Neoplasia, 13, 406–418. https://doi.org/10.1593/neo.101086CrossRefPubMedPubMedCentral

53.

Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., et al. (1996). TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell, 86, 531–542. https://doi.org/10.1016/S0092-8674(00)80127-0CrossRefPubMed

54.

Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., et al. (2002). Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of Clinical Investigation, 109, 1551–1559. https://doi.org/10.1172/JCI0215234CrossRefPubMedPubMedCentral

55.

Ischenko, I., Liu, J., Petrenko, O., & Hayman, M. J. (2014). Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells. Cell Death and Differentiation, 21, 1218–1228. https://doi.org/10.1038/cdd.2014.38CrossRefPubMedPubMedCentral

56.

Babic, A. M., Chen, C. C., & Lau, L. F. (1999). Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Molecular and Cellular Biology, 19, 2958–2966. https://doi.org/10.1128/MCB.19.4.2958CrossRefPubMedPubMedCentral

57.

Abreu, J. G., Ketpura, N. I., Reversade, B., & De Robertis, E. M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nature Cell Biology, 4, 599–604. https://doi.org/10.1038/ncb826CrossRefPubMedPubMedCentral

58.

Chang, C. C., Hsu, W. H., Wang, C. C., Chou, C. H., Kuo, M. Y., Lin, B. R., et al. (2013). Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Research, 73, 4147–4157. https://doi.org/10.1158/0008-5472.CAN-12-4085CrossRefPubMed

59.

Cook, D. P., & Vanderhyden, B. C. (2020). Context specificity of the EMT transcriptional response. Nature Communications, 11(1), 2142. https://doi.org/10.1038/s41467-020-16066-2CrossRefPubMedPubMedCentral

60.

Karacosta, L. G., Anchang, B., Ignatiadis, N., Kimmey, S. C., Benson, J. A., Shrager, J. B., et al. (2019). Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nature Communications, 10, 5587. https://doi.org/10.1038/s41467-019-13441-6CrossRefPubMedPubMedCentral

61.

Du, J., Zu, Y., Li, J., Du, S., Xu, Y., Zhang, L., et al. (2016). Extracellular matrix stiffness dictates Wnt expression through integrin pathway. Science and Reports, 6, 20395. https://doi.org/10.1038/srep20395CrossRef

62.

Bastide, P., Darido, C., Pannequin, J., Kist, R., Robine, S., Marty-Double, C., et al. (2007). Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. Journal of Cell Biology, 178, 635–648. https://doi.org/10.1083/jcb.200704152CrossRefPubMedPubMedCentral

63.

Diepenbruck, M., Waldmeier, L., Ivanek, R., Berninger, P., Arnold, P., Van Nimwegen, E., et al. (2014). Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. Journal of Cell Science, 127, 1523–1536. https://doi.org/10.1242/jcs.139865CrossRefPubMed

64.

Easwaran, H., Tsai, H. C., & Baylin, S. B. (2014). Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Molecular Cell, 54, 716–727. https://doi.org/10.1016/j.molcel.2014.05.015CrossRefPubMedPubMedCentral

65.

Liu, A., Yu, X., & Liu, S. (2013). Pluripotency transcription factors and cancer stem cells: Small genes make a big difference. Chinese Journal of Cancer, 32, 483–487. https://doi.org/10.5732/cjc.012.10282CrossRefPubMedPubMedCentral

66.

Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., et al. (2017). Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discovery, 7, 736–749. https://doi.org/10.1158/2159-8290.CD-16-1174CrossRefPubMedPubMedCentral

67.

Tata, P. R., Chow, R. D., Saladi, S. V., Tata, A., Konkimalla, A., Bara, A., et al. (2018). Developmental history provides a roadmap for the emergence of tumor plasticity. Dev Cell, 44, 679-693e5.CrossRefPubMedPubMedCentral

68.

Vrba, L., Jensen, T. J., Garbe, J. C., Heimark, R. L., Cress, A. E., Dickinson, S., et al. (2010). Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE, 5, e8697. https://doi.org/10.1371/journal.pone.0008697CrossRefPubMedPubMedCentral

69.

Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., et al. (2019). Author Correction: LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Science and Reports, 9, 18771. https://doi.org/10.1038/s41598-019-55020-55021CrossRef

70.

Lu, W., & Kang, Y. (2019). Epithelial-mesenchymal plasticity in cancer progression and metastasis. Developmental Cell, 49, 361–374. https://doi.org/10.1016/j.devcel.2019.04.010CrossRefPubMedPubMedCentral

71.

Herranz, N., Pasini, D., Diaz, V. M., Franci, C., Gutierrez, A., Dave, N., et al. (2008). Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Molecular and Cellular Biology, 28, 4772–4781. https://doi.org/10.1128/MCB.00323-08CrossRefPubMedPubMedCentral

72.

Chung, V. Y., Tan, T. Z., Ye, J., Huang, R. L., Lai, H. C., Kappei, D., et al. (2019). The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. Commun Biol, 2, 272. https://doi.org/10.1038/s42003-019-0506-3CrossRefPubMedPubMedCentral

73.

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National academy of Sciences of the United States of America, 100, 11606–11611. https://doi.org/10.1073/pnas.1933744100CrossRefPubMedPubMedCentral

74.

Ruscetti, M., Dadashian, E. L., Guo, W., Quach, B., Mulholland, D. J., Park, J. W., et al. (2016). HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene, 35, 3781–3795. https://doi.org/10.1038/onc.2015.444CrossRefPubMed

75.

Xiong, H. G., Li, H., Xiao, Y., Yang, Q. C., Yang, L. L., Chen, L., et al. (2019). Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research, 38, 278. https://doi.org/10.1186/s13046-019-1254-4CrossRef

76.

Topel, H., Bagirsakci, E., Comez, D., Bagci, G., Cakan-Akdogan, G., & Atabey, N. (2020). lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells. Cell Communication and Signaling: CCS, 18, 110. https://doi.org/10.1186/s12964-020-00602-0CrossRefPubMedPubMedCentral

77.

Daugaard, I., Sanders, K. J., Idica, A., Vittayarukskul, K., Hamdorf, M., Krog, J. D., et al. (2017). miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis, 6, e366. https://doi.org/10.1038/oncsis.2017.66CrossRefPubMedPubMedCentral

78.

Yan, L., Li, Y., Shi, Z., Lu, X., Ma, J., Hu, B., et al. (2017). The zinc finger E-box-binding homeobox 1 (Zeb1) promotes the conversion of mouse fibroblasts into functional neurons. Journal of Biological Chemistry, 292, 12959–12970. https://doi.org/10.1074/jbc.M116.771493CrossRefPubMedPubMedCentral

79.

Krebs, A. M., Mitschke, J., Losada, L. M., Schmalhofer, O., Boerries, M., Busch, H., et al. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 19, 518–529. https://doi.org/10.1038/ncb3513CrossRefPubMed

80.

Phillips, S., & Kuperwasser, C. (2014). SLUG: Critical regulator of epithelial cell identity in breast development and cancer. Cell AdhesMigr, 8, 578–587. https://doi.org/10.4161/19336918.2014.972740CrossRef

81.

Zhou, W., Lv, R., Qi, W., Wu, D., Xu, Y., Liu, W., et al. (2014). Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PLoS ONE, 9, e87409. https://doi.org/10.1371/journal.pone.0087409CrossRefPubMedPubMedCentral

82.

Gras, B., Jacqueroud, L., Wierinckx, A., Lamblot, C., Fauvet, F., Lachuer, J., et al. (2014). Snail Family Members Unequally Trigger EMT and Thereby Differ in Their Ability to Promote the Neoplastic Transformation of Mammary Epithelial Cells. PLoS ONE, 9(3), e92254. https://doi.org/10.1371/journal.pone.0092254CrossRefPubMedPubMedCentral

83.

Ye, X., Tam, W. L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Eaton, E. N., et al. (2015). Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature, 525(7568), 256–260. https://doi.org/10.1038/nature14897CrossRefPubMedPubMedCentral

84.

Subbalakshmi, A. R., Sahoo, S., Biswas, K., & Jolly, M. K. (2021). A computational systems biology approach identifies SLUG as a mediator of partial epithelial-mesenchymal transition (EMT). Cells Tissues Organs. https://doi.org/10.1159/000512520CrossRefPubMed

85.

Fabisiewicz, A., Szostakowska-Rodzos, M., Zaczek, A. J., & Grzybowska, E. A. (2020). Circulating tumor cells in early and advanced breast cancer; biology and prognostic value. International Journal of Molecular Sciences, 21, 1671. https://doi.org/10.3390/ijms21051671CrossRefPubMedCentral

86.

Sterneck, E., Poria, D. K., & Balamurugan, K. (2020). Slug and E-Cadherin: Stealth accomplices? Frontiers in Molecular Biosciences, 7, 138. https://doi.org/10.3389/fmolb.2020.00138CrossRefPubMedPubMedCentral

87.

Beck, B., Lapouge, G., Rorive, S., Drogat, B., Desaedelaere, K., Delafaille, S., et al. (2015). Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell, 16, 67–79. https://doi.org/10.1016/j.stem.2014.12.002CrossRefPubMed

88.

Aiello, N. M., Brabletz, T., Kang, Y., Nieto, M. A., Weinberg, R. A., & Stanger, B. Z. (2017). Upholding a role for EMT in pancreatic cancer metastasis. Nature, 547, E7–E8. https://doi.org/10.1038/nature22963CrossRefPubMedPubMedCentral

89.

Sahoo, S., Mishra, A., Kaur, H., Hari, K., Muralidharan, S., Mandal, S., et al. (2021). A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cells. NAR Cancer, 3(3), zcab027. https://doi.org/10.1093/narcan/zcab027CrossRefPubMedPubMedCentral

90.

Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22, 725–736. https://doi.org/10.1016/j.ccr.2012.09.022CrossRefPubMedPubMedCentral

91.

Stankic, M., Pavlovic, S., Chin, Y., Brogi, E., Padua, D., Norton, L., et al. (2013). TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Reports, 5, 1228–1242. https://doi.org/10.1016/j.celrep.2013.11.014CrossRefPubMed

92.

Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P., Jr., Frankel, S. R., Murty, V. V., et al. (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663–674. https://doi.org/10.1016/0092-8674(91)90112-cCrossRefPubMed

93.

Kersten, S., Desvergne, B., & Wahli, W. (2000). Roles of PPARs in health and disease. Nature, 405, 421–424. https://doi.org/10.1038/35013000CrossRefPubMed

94.

Zheng, Z. H., Yang, Y., Lu, X. H., Zhang, H., Shui, X. X., Liu, C., et al. (2011). Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ. European Journal of Pharmacology, 658, 1–8. https://doi.org/10.1016/j.ejphar.2011.01.068CrossRefPubMed

95.

Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., Saliba, J., Massonnet, G., et al. (2015). Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature, 525, 380–383. https://doi.org/10.1038/nature15248CrossRefPubMed

96.

Pestereva, E., Kanakasabai, S., & Bright, J. J. (2012). PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. British Journal of Cancer, 106, 1702–1712. https://doi.org/10.1038/bjc.2012.161CrossRefPubMedPubMedCentral

97.

Ishay-Ronen, D., Diepenbruck, M., Kalathur, R. K. R., Sugiyama, N., Tiede, S., Ivanek, R., et al. (2019). Gain fat-lose metastasis: Converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell, 35, 17-32.e16. https://doi.org/10.1016/j.ccell.2018.12.002CrossRefPubMed

98.

Melzer, C., VonderOhe, J., & Hass, R. (2018). Concise review: Crosstalk of mesenchymal stroma/stem-like cells with cancer cells provides therapeutic potential. Stem Cells, 36, 951–968. https://doi.org/10.1002/stem.2829CrossRefPubMed

99.

Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., et al. (2016). Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 22, 298–305. https://doi.org/10.1038/nm.4045CrossRefPubMedPubMedCentral

100.

Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C. C., et al. (2017). SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science, 355, 84–88. https://doi.org/10.1126/science.aah4307CrossRefPubMedPubMedCentral

101.

Soundararajan, R., Aparicio, A. M., Logothetis, C. J., Mani, S. A., & Maity, S. N. (2018). Function of tumor suppressors in resistance to antiandrogen therapy and luminal epithelial plasticity of aggressive variant neuroendocrine prostate cancers. Frontiers in Oncology, 8, 69. https://doi.org/10.3389/fonc.2018.00069CrossRefPubMedPubMedCentral

102.

Izumi, K., Fang, L. Y., Mizokami, A., Namiki, M., Li, L., Lin, W. J., et al. (2013). Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Molecular Medicine, 5, 1383–1401. https://doi.org/10.1002/emmm.201202367CrossRefPubMedPubMedCentral

103.

Flores-Morales, A., Bergmann, T. B., Lavallee, C., Batth, T. S., Lin, D., Lerdrup, M., et al. (2019). Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer. Clinical Cancer Research, 25, 595–608. https://doi.org/10.1158/1078-0432.CCR-18-0729CrossRefPubMed

104.

Li, Y., VandenBoom, T. G., Kong, D., Wang, Z., Ali, S., Philip, P. A., et al. (2009). Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Research, 69, 6704–6712. https://doi.org/10.1158/0008-5472.CAN-09-1298CrossRefPubMedPubMedCentral

105.

Meidhof, S., Brabletz, S., Lehmann, W., Preca, B. T., Mock, K., Ruh, M., et al. (2015). ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med, 7, 831–847. https://doi.org/10.15252/emmm.201404396CrossRefPubMedPubMedCentral

106.

Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y. K., Stoudemire, J., Smith, S., et al. (2017). Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs, 35, 180–188. https://doi.org/10.1007/s10637-016-0407-yCrossRefPubMed

107.

Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., et al. (2012). EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12, 91. https://doi.org/10.1186/1471-2407-12-91CrossRefPubMedPubMedCentral

108.

Scherbakov, A. M., Andreeva, O. E., Shatskaya, V. A., & Krasil’nikov, M. A. (2012). The relationships between snail1 and estrogen receptor signaling in breast cancer cells. Journal of Cellular Biochemistry, 113, 2147–2155. https://doi.org/10.1002/jcb.24087CrossRefPubMed

109.

Sánchez Tilló, E., Fanlo, L., Siles, L., Montes-Moreno, S., Moros, A., Chiva-Blanch, G., et al. (2014). The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death and Differentiation, 21, 247–257. https://doi.org/10.1038/cdd.2013.123CrossRefPubMed

110.

Loh, Y. N., Hedditch, E. L., Baker, L. A., Jary, E., Ward, R. L., & Ford, C. E. (2013). The Wntsignalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer, 13, 174. https://doi.org/10.1186/1471-2407-13-174CrossRefPubMedPubMedCentral

111.

Buonato, J. M., & Lazzara, M. J. (2014). ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Research, 74, 309–319. https://doi.org/10.1158/0008-5472.CAN-12-4721CrossRefPubMed

112.

Sun, N.-Y., & Yang, M.-H. (2020). Metabolic reprogramming and Epithelial-mesenchymal plasticity: Opportunities and challenges for cancer therapy. Frontiers in Oncology, 10, 792. https://doi.org/10.3389/fonc.2020.00792CrossRefPubMedPubMedCentral

113.

Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., et al. (2015). Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene, 34(30), 3908–3916.CrossRefPubMed

114.

Liu, H., Ma, Y., He, H. W., Zhao, W. L., & Shao, R. G. (2017). SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells. Autophagy, 13, 900–913. https://doi.org/10.1080/15548627.2017.1291479CrossRefPubMedPubMedCentral

115.

Xu, C. Y., Liu, S. Q., Qin, M. B., Zhuge, C. F., Qin, L., Qin, N., et al. (2017). SphK1 modulates cell migration and EMT-related marker expression by regulating the expression of p-FAK in colorectal cancer cells. International Journal of Molecular Medicine, 39, 1277–1284. https://doi.org/10.3892/ijmm.2017.2921CrossRefPubMed

116.

Zeng, Y., Yao, X., Chen, L., Yan, Z., Liu, J., Zhang, Y., et al. (2016). Sphingosine 1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-beta autocrine loop. Oncotarget, 7, 63324–37. https://doi.org/10.18632/oncotarget.11450CrossRefPubMedPubMedCentral

117.

Ito, H., Duxbury, M., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004). Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery, 136, 548–556. https://doi.org/10.1016/j.surg.2004.05.032CrossRefPubMed

118.

Li, J., Dong, L., Wei, D., Wang, X., Zhang, S., & Li, H. (2014). Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells. International Journal of Biological Sciences, 10(2), 171–180. https://doi.org/10.7150/ijbs.7357CrossRefPubMedPubMedCentral

119.

Hari, K., Sabuwala, B., Subramani, B. V., La Porta, C. A. M., Zapperi, S., Font-Clos, F., et al. (2020). Identifying inhibitors of epithelial-mesenchymal plasticity using a network topology-based approach. NPJ Syst Biol Appl, 6(1), 15. https://doi.org/10.1038/s41540-020-0132-1CrossRefPubMedPubMedCentral

120.

Celià-Terrassa, T., Bastian, C., Liu, D. D., Ell, B., Aiello, N. M., Wei, Y., et al. (2018). Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nature Communications, 9, 5005. https://doi.org/10.1038/s41467-018-07538-7CrossRefPubMedPubMedCentral

Titel: Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance
verfasst von: Minal Garg
Publikationsdatum: 03.01.2022
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2022
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-021-10003-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective

COVID-19 and cancer: start the resolution!

Glioma: molecular signature and crossroads with tumor microenvironment

Glycosylation as a regulator of site-specific metastasis

The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers

Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie